Table 1 Patient characteristics and graft composition.

From: Results of a multicenter phase I/II trial of TCRαβ and CD19-depleted haploidentical hematopoietic stem cell transplantation for adult and pediatric patients

Patients

Diagnosis (n = 60)

  AML

25

  ALL

17

  MDS/MPS

6

  MM, relapsed or refractory

1

  Acute undifferentiated leukemia

1

  Non-malignant diseases

4

  Solid tumors

6

Agea (years)

18.5 (1–63)

Weighta (kg)

54.1 (10.8–143)

Disease status prior to haplo HSCT

Pat. with malignancy and 1st HSCT

36

   CR1

12

   >CR1

13

   PR

1

   SD

2

   Non-remission

8

Pat. with malignancy and subsequent HSCT

20

   >CR1

13

   PR

1

   Non-remission

6

Graft compositiona (cells/kg)

  Stem cells (CD34+)

12.1 × 106 (4.0–54.9)

  TCRαβ+ cells

14.2 × 103 (2.2–64.3)

  TCRγδ+ cells

10.4 × 106 (1.1–45.0)

  B cells (CD20+)

3.8 × 104 (0.2–72.7)

  NK cells (CD56+)

45.3 × 106 (6.8–182.2)

  1. AML acute myeloid leukemia, ALL acute lymphoblastic leukemia, CR complete remission, HSCT hematopoietic stem cell transplantation, MDS/MPS myelodysplastic or myeloproliferative syndrome, MM multiple myeloma, PR partial remission, SD stable disease; disease status: degree of remission achieved after chemotherapy prior to study HSCT (haplo HSCT), Pat. with 1st HSCT these patients received their 1st HSCT within this study, Pat. with subsequent HSCT these patients had relapsed after previous HSCTs and received a 2nd or 3rd HSCT within this study.
  2. aMedian values.
Back to article page